Seres Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Seres Therapeutics, Inc. on June 22, 2022. The record date for the meeting was April 25, 2022.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
A total of 78,371,808 shares were present electronically or by proxy, representing approximately 84.97% of outstanding common stock. All three proposals were approved:
- Item 1 (Election of Directors): Three Class I directors were elected to serve until the 2025 Annual Meeting.
- Dennis A. Ausiello, M.D.: 62,542,177 votes FOR.
- Willard H. Dere, M.D.: 64,782,980 votes FOR.
- Eric D. Shaff: 64,876,769 votes FOR.
- Item 2 (Auditor Ratification): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2022, with 78,175,646 votes FOR.
- Item 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 70,250,385 votes FOR.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the full text of the Definitive Proxy Statement filed on April 29, 2022, for detailed background on the director nominees and executive compensation.
- Confirm the total number of outstanding shares as of the April 25, 2022 record date to contextualize the 84.97% participation rate.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.